Sign in
TerminatedNo phase

Integrating ePReBMs From Phoenix in Respiratory Diseases

Key facts

Who runs it
University of Alberta
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
7 people enrolled
Started
11 Oct 2023
Ended
6 May 2024
Type of study
Interventional
Treatments tested
  • Health Gauge AI-Based Wearable Device - Model: Phoenix
Record updated
29 October 2024
Why it stopped
Resource Issues

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Male or female volunteers, at least 18 years of age at the time of screening visit
  • Fluent in English and able to follow the instructions to use the Health Gauge AI-based Wearable Device
  • Willing and cognitively able to sign informed consent
  • Interstitial lung disease, chronic obstructive pulmonary disease, pulmonary hypertension, or a healthy control

Who cannot take part

  • Subjects with electronic implants of any kind (e.g. pacemaker)
  • An active medical conditions for which they are on chronic treatment with drugs
  • History of active (clinically significant) skin disorders
  • History of allergic response to plastic materials
  • Pregnancy
  • Broken, damaged or irritated skin or rashes near the sensor application sites
  • Subjects who are physically or cognitively unable to normally perform activities of daily living, assessed at the discretion of the investigator
  • Shortness of breath (any sort)
  • Chronic cough
  • Fatigue or difficulty sleeping

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Participants with respiratory disease experience often a worsening of their condition, with increasing symptoms such as cough and shortness of breath. This worsening, often called exacerbation or flare up, impacts on the life of the participants, since they become limited in their daily activities.

Read full original descriptionShow less

Healthcare is still based today on limited times for clinical appointments to perform investigations and to meet with specialists/clinicians. Very often, these evaluations do not reflect the way the disease is limiting the patient's life.

Wearable devices offer the opportunity to collect data on physical activities and important clinical parameters (such as how the patient is active or just staying in bed during the day), on a daily basis.

The HG Phoenix AI- based Smart Watch produced by Health Gauge, an Albertan company based in Edmonton, has the potential to measure heart rate, heart rate variability, blood pressure, pulse wave velocity, respiratory rate, temperature, arterial saturation, sleep pattern (deep, light sleep, awake time), duration and time, daily physical activities (site count and distance) and calories burnt in a simple and non-invasive fashion. Ideally, these parameters could be monitored and recorded 24 hours per 7 days per week.

This study aims to demonstrate that this device can be used for a long time at home and it is comfortable to use for the participants, that it is not dangerous and, possibly, that it can help to identify exacerbations before the currently available investigations.

The group in the trial

  • Device: Health Gauge AI-Based Wearable Device - Model: PhoenixTreatment being tested

    Treatment: Health Gauge AI-Based Wearable Device - Model: Phoenix

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Integrating Electronic Patient Reported Biometric Measures (ePReBMs) From the Health Gauge Phoenix Smart Watch in Respiratory Diseases
Record updated
29 October 2024